Pharmacokinetics, safety, and efficacy of a new high-purity plasma-derived factor X concentrate in female subjects with hereditary factor X deficiency
Conferences
James, A; Shapiro, A; Norton, M
Published in: HAEMOPHILIA
July 1, 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
HAEMOPHILIA
EISSN
1365-2516
ISSN
1351-8216
Publication Date
July 1, 2016
Volume
22
Start / End Page
136 / 136
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
James, A., Shapiro, A., & Norton, M. (2016). Pharmacokinetics, safety, and efficacy of a new high-purity plasma-derived factor X concentrate in female subjects with hereditary factor X deficiency. In HAEMOPHILIA (Vol. 22, pp. 136–136). WILEY-BLACKWELL.
James, Andra, Amy Shapiro, and Miranda Norton. “Pharmacokinetics, safety, and efficacy of a new high-purity plasma-derived factor X concentrate in female subjects with hereditary factor X deficiency.” In HAEMOPHILIA, 22:136–136. WILEY-BLACKWELL, 2016.
James A, Shapiro A, Norton M. Pharmacokinetics, safety, and efficacy of a new high-purity plasma-derived factor X concentrate in female subjects with hereditary factor X deficiency. In: HAEMOPHILIA. WILEY-BLACKWELL; 2016. p. 136–136.
James, Andra, et al. “Pharmacokinetics, safety, and efficacy of a new high-purity plasma-derived factor X concentrate in female subjects with hereditary factor X deficiency.” HAEMOPHILIA, vol. 22, WILEY-BLACKWELL, 2016, pp. 136–136.
James A, Shapiro A, Norton M. Pharmacokinetics, safety, and efficacy of a new high-purity plasma-derived factor X concentrate in female subjects with hereditary factor X deficiency. HAEMOPHILIA. WILEY-BLACKWELL; 2016. p. 136–136.
Published In
HAEMOPHILIA
EISSN
1365-2516
ISSN
1351-8216
Publication Date
July 1, 2016
Volume
22
Start / End Page
136 / 136
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences